WIPO side event, December 6, 2018, on the Implications of Article 27.3(a) of the WTO TRIPS Agreement on the patentability of gene and cell-based therapies

DATE: Thursday, 6 December 2018 TIME: 1:30 PM to 3 PM VENUE: Room B CONVENER: Knowledge Ecology International (KEI) Knowledge Ecology International (KEI) cordially invites you to attend our side event during negotiations of the 29th Session of the Standing… Continue Reading

2018: NIH licenses on Anti-Mesothelin CAR to Atara Biotherapeutics

Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics… Continue Reading

Litigation: KEI v. NIH et al.

On April 19, 2018, KEI filed a lawsuit against the NIH license of CD30 CAR T patents to Gilead. On April 11, 2019, the lawsuit was dismissed on the grounds that KEI lacked standing. KEI blogs January 5, 2018. 2018: Briefing note… Continue Reading

KEI Appeals NIH/NCI Decision to Proceed with License of CD30 CAR T technology to Gilead/Kite

KEI has appealed the NIH/NCI decision to proceed with the proposed exclusive license of anti-CD30 CAR T to Gilead, following an email of January 25, 2018 from Dr. David Lambertson of NCI rejecting all of KEI’s substantive suggestions and objections. KEI… Continue Reading

FTC approves Celgene acquisition of Juno without requiring divestitures

On Tuesday February 20, 2018, the U.S. Federal Trade Commission approved the Celgene acquisition of Juno, without requiring divestitures. The European Commission did not review the merger. KEI’s February 16, 2018 letter opposing the acquisition is available here. The following… Continue Reading

KEI asks FTC to block Celgene Acquisition of Juno​ Therapeutics, over BCMA-targeted CAR T treatment for Multiple Myeloma

On February 14, 2018, KEI meet with the FTC to express our opposition to Celgene’s proposed acquisition of Juno Therapeutics. Celgene-Juno-KEI-FTC16Feb2018 The Celgene acquisition of Juno Therapeutics would give Celgene control over competing candidates for the treatment of multiple myeloma… Continue Reading

NIH Declines Request for the Budget for Clinical Trials Involving CAR T technology to be licensed to Kite/Gilead

On February 14, the NIH was asked what the budget was for the Phase 1 clinical trial of the anti-CD30 CAR T technology that is the subject of a proposed exclusive patent license to Kite/Gilead. The clinicaltrials.gov identifier for the… Continue Reading